Cyclopropanecarboxylic Acid Amide

Cyclopropanecarboxylic Acid Amide

SCHEMBL2861585

NC(=O)C1CC1.O=C(O)c1ccc2[nH]nc(-c3ccc4ccccc4c3)c2c1F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BTK Q06187 1/20 0.39
CA12 O43570 1/20 0.38
F11 P03951 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
MAP2K4 P45985 2/20 0.37
TTK P33981 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MIF P14174 1/20 0.37
ACMSD Q8TDX5 1/20 0.36
GSK3B P49841 1/20 0.36
VCP P55072 1/20 0.36
DHODH Q02127 1/20 0.35
LRRK2 Q5S007 1/20 0.35
CDK4 P11802 1/20 0.35
CCNA2 P20248 1/20 0.35
CCND1 P24385 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857443 0.90 CA12 (0.46) BTKCA12MAPKAPK2MAP2K4MEN1
Cyclopropanecarboxylic Acid Amide SCHEMBL2864932 0.82 SIRT2 (0.48) NPC1RAB9ASMN1; SMN2CA12MEN1
Cyclopropanecarboxylic Acid Amide SCHEMBL2857322 0.82 SIRT2 (0.48) BTKCA12MAPKAPK2
SCHEMBL2861587 0.80 KDR (0.49) NPC1RAB9AGSK3BLRRK2KDR
SCHEMBL4336796 0.78 GSK3B (0.49) GSK3BMAPK14
SCHEMBL2867525 0.77 ALPL (0.50) SMN1; SMN2CA12MAPKAPK2MAP2K4CDK4
SCHEMBL4339304 0.76 SCN9A (0.39) MAPKAPK2MAP2K4TTKCDK4CCNA2
SCHEMBL2863486 0.74 MAP2K4 (0.52) MAP2K4TTKGSK3BDHODHKDR
SCHEMBL2861482 0.74 CDK4 (0.48) NPC1RAB9ASMN1; SMN2BTKCA12
SCHEMBL2863193 0.74 MAPKAPK2 (0.46) NPC1RAB9ASMN1; SMN2BTKMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 NPC1 1164/4885RAB9A 2355/4885SMN1; SMN2 4812/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 NPC1 1171/4885RAB9A 2697/4885SMN1; SMN2 4781/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 NPC1 1164/4885RAB9A 2355/4885SMN1; SMN2 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.